These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29978754)

  • 21. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Tang CPS; McMullen J; Tam C
    Leuk Lymphoma; 2018 Jul; 59(7):1554-1564. PubMed ID: 28901789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
    Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.
    Cherng HJ; Khwaja R; Kanagal-Shamanna R; Tang G; Burger J; Thompson P; Ferrajoli A; Estrov Z; Sasaki K; Sampath D; Wang X; Kantarjian H; Keating M; Wierda WG; Jain N
    Am J Hematol; 2022 Aug; 97(8):1005-1012. PubMed ID: 35567779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    Byrd JC; Harrington B; O'Brien S; Jones JA; Schuh A; Devereux S; Chaves J; Wierda WG; Awan FT; Brown JR; Hillmen P; Stephens DM; Ghia P; Barrientos JC; Pagel JM; Woyach J; Johnson D; Huang J; Wang X; Kaptein A; Lannutti BJ; Covey T; Fardis M; McGreivy J; Hamdy A; Rothbaum W; Izumi R; Diacovo TG; Johnson AJ; Furman RR
    N Engl J Med; 2016 Jan; 374(4):323-32. PubMed ID: 26641137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BTK Inhibitors and Chemoimmunotherapy for CLL.
    Thompson P
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
    Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
    [No Abstract]   [Full Text] [Related]  

  • 31. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
    Stephens DM
    J Clin Oncol; 2021 Nov; 39(31):3419-3422. PubMed ID: 34310198
    [No Abstract]   [Full Text] [Related]  

  • 35. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
    Bossory Goike L; Dean S
    Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868
    [No Abstract]   [Full Text] [Related]  

  • 36. The current status and future trends of BTK inhibitor for diffuse large B cell lymphoma.
    Chen Q; Xu L; Lu C; Wang C; Yu L
    Pharmacol Res; 2024 Sep; 207():107337. PubMed ID: 39094986
    [No Abstract]   [Full Text] [Related]  

  • 37. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
    Chen D; Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
    Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
    Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib-Induced Lymphocytosis: Cytological Features.
    Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
    Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
    [No Abstract]   [Full Text] [Related]  

  • 40. Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday.
    Jiang R; Li JY; Zhu HY
    Curr Med Sci; 2021 Jun; 41(3):431-442. PubMed ID: 34181208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.